Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]
In development [GID-TA10631] Expected publication date: TBC
Search results
496 results
-
-
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353
In development [GID-TA10320] Expected publication date: TBC
-
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
In development [GID-TA10620] Expected publication date: TBC
-
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]
In development [GID-TA10489] Expected publication date: TBC
-
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]
In development [GID-TA10377] Expected publication date: TBC
-
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]
In development [GID-TA10259] Expected publication date: TBC
-
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147
In development [GID-TA10343] Expected publication date: TBC
-
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]
In development [GID-TA10484] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]
In development [GID-TA10693] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]
In development [GID-TA10692] Expected publication date: TBC
-
Lifitegrast for treating dry eye disease [ID1229]
In development [GID-TA10196] Expected publication date: TBC
-
Abicipar pegol for treating wet age-related macular degeneration ID1533
In development [GID-TA10511] Expected publication date: TBC
-
Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]
In development [GID-TA10442] Expected publication date: TBC
-
Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: TBC
-
Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]
In development [GID-TA10209] Expected publication date: TBC
-
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [ID1457]
In development [GID-TA10690] Expected publication date: TBC
-
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083]
In development [GID-TA10260] Expected publication date: TBC
-
Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588
In development [GID-TA10507] Expected publication date: TBC
-
Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]
In development [GID-TA10614] Expected publication date: 23 June 2021
-
Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]
In development [GID-TA10618] Expected publication date: 23 June 2021
-
Budesonide for treating active eosinophilic oesophagitis [ID1202]
In development [GID-TA10372] Expected publication date: 23 June 2021
-
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]
In development [GID-TA10370] Expected publication date: TBC
-
Baloxavir marboxil for treating influenza [ID1537]
In development [GID-TA10559] Expected publication date: TBC
-
Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]
In development [GID-TA10544] Expected publication date: TBC
-
Apalutamide for treating prostate cancer [ID1534]
In development [GID-TA10423] Expected publication date: 26 May 2021
-
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]
In development [GID-TA10491] Expected publication date: TBC
-
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]
In development [GID-TA10615] Expected publication date: TBC
-
Breast cancer (brain metastases) - etirinotecan pegol [ID881]
In development [GID-TA10066] Expected publication date: TBC
-
Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275
In development [GID-TA10375] Expected publication date: TBC
-
Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]
In development [GID-TA10570] Expected publication date: 17 November 2021
-
Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]
In development [GID-TA10387] Expected publication date: TBC
-
Midostaurin for treating advanced systemic mastocytosis ID1573
In development [GID-TA10503] Expected publication date: TBC
-
Melanoma (metastatic) - talimogene laherparepvec [ID508]
In development [GID-TAG509] Expected publication date: 28 September 2016
-
Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]
In development [GID-TA10026] Expected publication date: TBC
-
Psoriasis - briakinumab (suspended) [ID65]
In development [GID-TAG412] Expected publication date: TBC
-
Osteoarthritis - naproxcinod [ID417]
In development [GID-TAG426] Expected publication date: TBC
-
Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]
In development [GID-TAG418] Expected publication date: TBC
-
Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]
In development [GID-TAG456] Expected publication date: TBC
-
Leukaemia (acute lymphoblastic) - dasatinib [ID386]
In development [GID-TAG399] Expected publication date: TBC
-
Renal cell carcinoma (second line metastatic) - pazopanib [ID70]
In development [GID-TAG398] Expected publication date: 01 January 2011
-
Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]
In development [GID-TAG414] Expected publication date: TBC
-
Diabetic foot ulcers - new treatments [ID381]
In development [GID-TAG371] Expected publication date: TBC
-
Venous leg ulcers - new treatments [ID394]
In development [GID-TAG370] Expected publication date: TBC
-
Venous thromboembolism (VTE) - ximelagatran [ID396]
In development [GID-TAG378] Expected publication date: TBC
-
OTL-200 for treating metachromatic leukodystrophy [ID1666]
In development [GID-HST10028] Expected publication date: 13 August 2021
-
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
In development [GID-TA10597] Expected publication date: 27 October 2021
-
Nivolumab with ipilimumab and chemotherapy for untreated advanced non-small-cell lung cancer [ID1566]
In development [GID-TA10472] Expected publication date: 02 June 2021
-
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]
In development [GID-TA10493] Expected publication date: TBC